Effect of Early Treatment with Ivermectin among Patients with Covid-19 – PubMed
Therapy started late, medium not high dose, only 3 days, not a comprehensive vitamin program with it, and still trends to benefit. Pharma sponsored
Related Articles
Hospital Consolidation and Physician Unionization | NEJM
Most physicians now face the experience of being employees of hospitals or other large organizations. Unionization is a natural consequence of consolidation and the corporatization…
Current Issue | NEJM Catalyst Innovations in Care Delivery
Explore the current issue of NEJM Catalyst Innovations in Care Delivery (Vol. 5 No. 5).
A Practical Guide for Implementing the Digital Healthcare Equity Framework | Digital Healthcare Research
Use of digital healthcare technologies – for clinicians and patients – is growing. To ensure these solutions benefit all patient groups, creators and users must be…
The People’s President of HSPA: An Exclusive Conversation With Anthony Bondon, CRCST, CHL, BSM, AAS, SME, LSSYB
HSPA’s 2024-2025 president, Anthony Bondon, CRCST, CHL, BSM, AAS, SME, LSSYB, spoke with Infection Control Today to discuss his goals for his tenure and more.
Epilepsy Drug Use in Pregnancy and Major Congenital Malformation: What’s the Link?
In a prospective observational study, researchers compared the 8 most commonly used ASM monotherapies during pregnancy with regard to risk for MCMs in offspring of…
Diagnostic terminology for benign/low‐risk tumors on renal cytology
Cancer Cytopathology is an international cytopathology journal publishing research related to topics concerning the etiology of cancer, its diagnosis and prevention.
Colombia issues a compulsory license for an HIV medicine and ‘plants a flag for global health equity’
“Colombia is planting a flag for global health equity,” said Peter Maybarduk, who heads the access to medicines campaign at Public Citizen.
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
DESTINY-Breast03 is a randomized, multicenter, open-label, phase III study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor…
Sports and Your Eyes | National Eye Institute
Eye injuries from sports are serious. The good news is that you can prevent most eye injuries by wearing the right protective eyewear. Check out…
What Can We Learn from the Unwinding of Continuous Medicaid Enrollment?
One year later, what have been the effects of unwinding Medicaid’s continuous enrollment policy that started during the COVID-19 pandemic?
